179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development

179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development

Bibliographic Details
Main Authors:	Razelle Kurzrock, Shumei Kato, Jacob Adashek, Alexey Goloubev
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
by: Jacob J. Adashek, et al.
Published: (2020-02-01)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
by: Jacob J. Adashek, et al.
Published: (2020-08-01)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
by: Philip R. Cohen, et al.
Published: (2017-07-01)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
by: Jacob J. Adashek, et al.
Published: (2021-07-01)

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
by: Mina Nikanjam, et al.
Published: (2017-08-01)

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
by: Shumei Kato, et al.
Published: (2021-01-01)

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
by: Jacob J. Adashek, et al.
Published: (2019-05-01)

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
by: Galina Khemlina, et al.
Published: (2017-08-01)

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
by: Amélie Boichard, et al.
Published: (2019-03-01)

spiritan_news_179

MHC-I genotype and tumor mutational burden predict response to immunotherapy
by: Aaron M. Goodman, et al.
Published: (2020-05-01)

Protection by exclusion? The (lack of) inclusion of adults who lack capacity to consent to research in clinical trials in the UK
by: Victoria Shepherd, et al.
Published: (2019-08-01)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
by: Ruchi Agashe, et al.
Published: (2020-08-01)

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response
by: Kripa Guram, et al.
Published: (2018-10-01)

Characterization of the molecular function of Znf179
by: Chien-Ying Lai, et al.
Published: (2014)

RECL 179 - 29-Jul-81
Published: (2011)

No.65,Ln.179,Sec.1
by: Wu, Jo Chen, et al.
Published: (2014)

Characterization of the ZNF179 promoter: identification of transcription factors that regulate ZNF179 expression during neural differentiation
by: I-Fang Wang, et al.
Published: (2009)

Letter on “Protection by exclusion? The (lack of) inclusion of adults who lack capacity to consent to research in clinical trials in the UK”
by: Sarah Griffiths, et al.
Published: (2020-01-01)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
by: Timothy V. Pham, et al.
Published: (2020-08-01)

Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
by: Karim Pérez-Romero, et al.
Published: (2020-08-01)

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
by: Denis L. Jardim, et al.
Published: (2020-01-01)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
by: Shu-Jen Chen, et al.
Published: (2020-06-01)

Diabetic Foot Infections: The Evaluation of 179 Cases
by: Sercan ULUSOY, et al.
Published: (2000-12-01)

RECL 179A - 29-Jul-81
Published: (2011)

RECL 179A - 15-Aug-82
Published: (2011)

RECL 179A - 24-Jul-83
Published: (2011)

Supply change mannagement - II179 201801
by: Ramos Palomino, Edgar David
Published: (2018)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
by: Aaron M. Goodman, et al.
Published: (2018-03-01)

Introducción A Los Negocios-AD179-201501
by: Lopez Calle Jose Luis, et al.
Published: (2020)

Introducción A Los Negocios-AD179-201502
by: Lopez Calle Jose Luis, et al.
Published: (2020)

Investigation of CEBPD-mediated ZNF179 transcription in astrocytes
by: Jing-FangHuang, et al.
Published: (2011)

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
by: Ziena Abdulrahman, et al.
Published: (2020-07-01)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
by: Lindsey M. Charo, et al.
Published: (2021-01-01)

Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy
by: Austin W. T. Chiang, et al.
Published: (2021-06-01)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
by: Ryosuke Okamura, et al.
Published: (2020-06-01)

Portafolio Y Tesis De Grado-DI179-201502
by: Pugliesi Acevedo Fiorella Roxana, et al.
Published: (2020)

Portafolio Y Tesis De Grado-DI179-201601
by: Guerra Espinoza Fiorella Vanessa, et al.
Published: (2020)

Portafolio Y Tesis De Grado-DI179-201602
by: Guerra Espinoza Fiorella Vanessa, et al.
Published: (2020)

Portafolio Y Tesis De Grado-DI179-201701
by: Ricci Garay Mario Alonso, et al.
Published: (2020)